Key Documents

View All Documentation

SML2156

Erlotinib hydrochloride

Name: Erlotinib hydrochloride
Brand: SIGMA

≥98% (HPLC), EGFR kinase inhibitor, powder

Synonym(s):

774 hydrochloride, CP-358, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, OSI-744 hydrochloride

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₃N₃O₄ · HCl

CAS Number:

183319-69-9

Molecular Weight:

429.90

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD07781272

Assay:

≥98% (HPLC)

Form:

powder

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Erlotinib hydrochloride, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

Cl.N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC

InChI

1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

InChI key

GTTBEUCJPZQMDZ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

General description

Erlotinib hydrochloride is an antineoplastic drug. It regulates mechanistic target of rapamycin (mTOR) inhibition, epidermal growth factor receptor down-regulation and epidermal interstitial transformation (EMT) suppression.

Application

Erlotinib hydrochloride has been used to activate mitochondrial fragmentation in a human PANC-1 pancreatic cancer cell line.

Biochem/physiol Actions

EGFR kinase inhibitor; Antineoplastic

Erlotinib hydrochloride is an inhibitor of the receptor tyrosine kinase EGFR (epidermal growth factor receptor). It is used clinically for the treatment of non-small cell lung cancer (NSCLC) and in combination for metastatic pancreatic cancer.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000507102

0000472016

0000455118

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death.

Rabea Oberthür et al.

Cancer letters, 407, 93-105 (2017-08-22)

Overexpression and activation of receptor tyrosine kinases (RTKs), such as the insulin-like growth factor 1 receptor (IGF1R) and the epidermal growth factor receptor (EGFR), are frequent phenomena in colorectal cancer (CRC). Here, we evaluated the effect and the cellular mechanisms

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

J D Moyer et al.

Cancer research, 57(21), 4838-4848 (1997-11-14)

The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype. CP-358,774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR

Analytical Methods for Therapeutic Drug Monitoring and Toxicology (2011)

Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy.

Kandasamy Saravanakumar et al.

Carbohydrate polymers, 245, 116407-116407 (2020-07-29)

The present work was developed the pH dependent-aptamer AS1411 (APT) decorated and erlotinib (En) loaded chitosan nanoparticles (CSNPs) for promising non-small-cell lung carcinoma (NSCLC) treatment. The characterization studies revealed that formulated APT-En-CSNPs were spherical in shape with size of 165.95

In vitro evidence for the potential of EGFR inhibitors to decrease the TGF-β1-induced dispersal of circulating tumour cell clusters mediated by EGFR overexpression.

Jorian D Hapeman et al.

Scientific reports, 14(1), 19980-19980 (2024-08-31)

Most cancer-related deaths are due to the spread of tumour cells throughout the body-a process known as metastasis. While in the vasculature, these cells are referred to as circulating tumour cells (CTCs) and can be found as either single cells

View All Related Papers

Global Trade Item Number

SKU	GTIN
SML2156-50MG	04061835502974
SML2156-100MG	04061835502981

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service